ESP | ENG

Listado Articulos

  1. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007; 51:191-6.
  2. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis. 2006 Aug;65(8):1117-8..
  3. Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005 Jul;64(7):1087-8.
  4. Ahmed MM, Mubashir E, Dossabhoy NR. Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab. Clin Rheumatol. 2007 Aug;26(8):1346-9.
  5. Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol. 2007 Aug;26(8):1353-5.
  6. Airò P, Antonioli CM, Vianelli M, Toniati P.Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford). 2002 Mar;41(3):347-9.
  7. Al-Bishri J, le Riche N, Pope JE.Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol. 2005 Jul;32(7):1371-3.
  8. Ali Y, Perlman E. Successful treatment of sarcoidosis. Ann Intern Med. 2004 Jun 1;140(11):W70.
  9. Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis. 2006 Jun;65(6):834-5.
  10. Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behcet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 2007; 109:279-81.
  11. Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann Hematol. 2007 Mar;86(3):227-8. ]
  12. Anandacoomarasamy A, Gibson J, McGill N. 'Cure' of life-threatening antiphospholipid syndrome with rituximab. Intern Med J. 2006 Jul;36(7):474-5
  13. Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory polymyositis responding to infliximab.Rheumatology (Oxford). 2005 Apr;44(4):562-3.
  14. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis. 2003 Nov;62(11):1116
  15. Andreu M, Ramanoelina J, Fajnkuchen F, et al. [Treatment of severe Behcet's disease with anti-TNF-alpha: infliximab. A case report]. Ann Med Interne (Paris) 2002; 153:414-5.
  16. Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM,Boumpas DT. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007 Jan-Feb;25(1):23-8.
  17. Arayssi T, Hamra R, Homeidan F, et al. The efficacy of a single dose of infliximab in the treatment of Behcet's disease uveitis. Clin Exp Rheumatol 2005; 23:427.
  18. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002 Dec;206(5):496-501.
  19. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-8.
  20. Aries PM, Reinhold-Keller E. [Symmetric polyarthritis in a patient with Churg-Strauss syndrome] Dtsch Med Wochenschr. 2005 Aug 19;130(33):1871-3.
  21. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004 Oct;50(10):3161-9.
  22. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006 Dec;65(12):1596-601.
  23. Armstrong DJ, McCarron MT, Wright GD. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int. 2006 Jun;26(8):771-2.
  24. Armstrong DJ, Wright SA, Finch MB, Taggart AJ, Bell AL. Active systemic lupus erythematosus successfully treated with Rituximab and oral steroid. Clin Exp Rheumatol 2004; 22:787-8.
  25. Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, Cervera R. Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases. Semin Arthritis Rheum. 2007 Oct 29;
  26. Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M. Successful treatment of resistant Behcet's disease with etanercept. Clin Exp Rheumatol 2005; 23:729.
  27. Bachmeyer C, Cadranel JF, Demontis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. 2005 Jun;20(6):1274.
  28. Baki K, Villiger PM, Jenni D, Meyer T, Beer JH. Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 2006; 65:1531-2.
  29. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab Treatment in a Patient with Systemic Sclerosis Associated with Luna Fibrosis and Pulmonary Hypertension. Respiration. 2005 Dec 9;
  30. Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006; 66:S123-4.
  31. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.Rheumatology (Oxford). 2002 Oct;41(10):1126-32.
  32. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation. 2005 Dec 15;80(11):1560-4.
  33. Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, Guitard J, Lavayssière L, Oksman F, Durand D, Rostaing L.Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc. 2006 Sep;38(7):2308-10.
  34. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795-802.
  35. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128:1062-47.
  36. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001 Mar;18(1):70-4.
  37. Bawa S, Mukhtyar C, Edmonds S, Webley M. Refractory Wegener's meningitis treated with rituximab. J Rheumatol. 2007 Apr;34(4):900-1.
  38. Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset. Still's disease: the first case report. Clin Exp Rheumatol. 2005 Sep-Oct;23(5):733.
  39. Bhatia A, Ell PJ, Edwards JC.Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005 Jul;64(7):1099-100.
  40. Bonilla Hernán MG, Cobo Ibáñez T, de Miguel Mendieta E, Martín-Mola E. [Infliximab (anti-TNF-alpha) treatment in patients with adult Still's disease.Experience in 2 cases]. An Med Interna. 2004 Jan;21(1):23-6.
  41. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-21.
  42. Braun A, Neumann T, Oelzner P, Hein G, Gröne HJ, Ziemer M, Wolf G. Cryoglobulinemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int. 2008 Mar; 28(5):503-506.
  43. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25:S23-7.
  44. Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006 Jul;65(7):974-5.
  45. Bryce AH, Dispenzieri A, Kyle RA, et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 2006; 7:140-4.
  46. Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, Kim JH, Song JK, Yoo B, Yu CS. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum. 2007 May;50(5):672-6.
  47. Cai FZ, Ahern M, Smith M.Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol. 2006 Jun;33(6):1197-8.
  48. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006 Jul;25(4):596-7.
  49. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001 Dec;44(12):2933-5.
  50. Caramaschi P, Biasi D, Carletto A, Bambara LM. A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol. 2002 Jan-Feb;20(1):113.
  51. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren's syndrome. Neurology. 2002 Oct 8;59(7):1113-4.
  52. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med. 2004 Aug 15;117(4):277-9.
  53. Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol. 2005 Jul;32(7):1413.
  54. Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 2007; 57:1514-9.
  55. Catuogno M, Rezai S, Priori R, Magrini L, Valesini G.Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford). 2005 Mar;44(3):406
  56. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol. 2001 May-Jun;19(3):329-32.
  57. Cazabon S, Over K, Butcher J.The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye. 2005 Feb;19(2):222-4.
  58. Chalam KV, Gupta SK, Agarwal S. Rituximab effectively reverses papilledema associated with cerebral venous sinus thrombosis in antiphospholipid antibody syndrome. Eur J Ophthalmol. 2007 Sep-Oct;17(5):867-70.
  59. Chandesris MO, Gayet S, Schleinitz N, Doudier B, Harlé JR, Kaplanski G. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia.Rheumatology (Oxford). 2004 Apr;43(4):532-3.
  60. Chávez-López M, Márquez-Díaz F, Aguayo-Leytte G.[Cerebral cryptococcosis associated with etanercept] Enferm Infecc Microbiol Clin. 2006 Apr;24(4):288.
  61. Chawla S, Smart CJ, Moots RJ. Recto-vaginal fistula: a refractory complication of Behcet's disease. Colorectal Dis. 2007 Sep;9(7):667-8.
  62. Chehab G, Sander O, Fischer-Betz R, Schneider M. [Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus]. Z Rheumatol 2007; 66:328, 330-6.
  63. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab.Br J Ophthalmol. 2005 Nov;89(11):1542.
  64. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005; 11:264-6.
  65. Chu D, Stevens M, Gladstone DE. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.Rheumatol Int. 2007 Oct;27(12):1173-5.
  66. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143:763-7.
  67. Clayton TH, Ogden S, Goodfield MD.Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol. 2006 May;54(5):892-5.
  68. Cohen H, Green S, Jones S, Amos N, William BD. Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia. Rheumatology (Oxford). 2007 Feb;46(2):366-7
  69. Connolly M, Armstrong JS, Buckley DA. Infliximab treatment for severe orogenital ulceration in Behcet's disease. Br J Dermatol 2005; 153:1073-5.
  70. Cruz BA, Reis DD, Araujo CA; Minas Gerais Vasculitis Study Group. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int. 2007 Oct;27(12):1181-3..
  71. Dechant C, Schauenberg P, Antoni CE, Kraetsch HG, Kalden JR, Manger B. [Longterm outcome of TNF blockade in adult-onset Still's disease]. Dtsch Med Wochenschr 2004; 129:1308-12.
  72. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57:310-7.
  73. Dilhuydy MS, Vatan R, Etienne G, Longy-Boursier M, Mercié P. Prolonged efficacy of infliximab for refractory adult-onset Still's disease.Clin Exp Rheumatol. 2005 Jan-Feb;23(1):121-2.
  74. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007; 56:148-53.
  75. Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007; 26:1186-8.
  76. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74.
  77. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127:1064-71.
  78. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006 Sep;65(9):1233-6.
  79. El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis.Eye. 2005 Sep;19(9):1017-8.
  80. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica. 2004 Sep;89(9):ECR34.
  81. Eriksson P.Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.J Intern Med. 2005 Jun;257(6):540-8.
  82. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). 2002 Oct;41(10):1213-4.
  83. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-61.
  84. Farah R, Lisitsin S, Shay M. Bacterial meningitis associated with infliximab. Pharm World Sci. 2006 Jun;28(3):123-5.
  85. Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005; 64:262-6.
  86. Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant. 2005 Mar;20(3):622-5.
  87. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005 Jun;52(6):1794-803.
  88. Fouchier SM, Möller GM, Van Santen-Hoeufft M, Faber CG, Smeenk FW, Drent M. [Successful treatment with infliximab of a patient with refractory sarcoidosis] Ned Tijdschr Geneeskd. 2004 Dec 4;148(49):2446-50.
  89. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12:783-7.
  90. Freidlin J, Wong IG, Acharya N.Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.Br J Ophthalmol. 2007 Oct;91(10):1414.
  91. Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007; 66:136-7.
  92. Garcia-Porrua C, Gonzalez-Gay MA.Successful response to infliximab in a patient with undifferentiated spondyloarthropathy coexisting with polyarteritis nodosa-like cutaneous vasculitis.Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S138
  93. Geetha D, Seo P, Specks U, Fervenza FC.Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases.Am J Transplant. 2007 Dec;7(12):2821-5.
  94. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D.Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure.Am J Kidney Dis. 2004 May;43(5):e34-8.
  95. Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA.Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response.Am J Hematol. 2004 Dec;77(4):329-30.
  96. Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol 2004; 14:445-8.
  97. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum 2007; 57:538-42.
  98. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, Rousset H, Salles G, Broussolle C, Sève P. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006;15(4):223-3
  99. Gonçalves TC, Massumoto CM, Siquiera R, Hanauer L, Costa LM, Gomes AP. The use of monoclonal antibody (Rituximab) in the treatment of type II mixed cryoglobulinemia. The Brazilian Journal of Infectious Disease 2007; 11 (1): 174 -175.
  100. Goossens PH, Verburg RJ, Breedveld FC.Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.Ann Rheum Dis. 2001 Jun;60(6):637.
  101. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007 Jan;35(1):66-9.
  102. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005 Jun;64(6):913-20
  103. Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol. 2007 Sep-Oct;25(5):758-9.
  104. Gulli S, Arrigo C, Bocchino L, Morgante L, Sangari D, Castagna I, Bagnato GF Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003 Aug 28;4:19.
  105. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56:1263-72.
  106. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio).Br J Dermatol. 2004 Jan;150(1):146-9.
  107. Hamaguchi M, Kawahito Y, Ishino H, Yoshida M, Yoshikawa T. A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol. 2007 Jun;26(6):988-90.
  108. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford). 2004 Oct;43(10):1309-10
  109. Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford). 2008 Feb;47(2):224-5.
  110. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA.Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.Gastroenterology. 2001 Mar;120(4):995-9.
  111. Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 2004; 63:744-5.
  112. Hayat SJ, Uppal SS, Narayanan Nampoory MR, Johny KV, Gupta R, Al-Oun M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol. 2007 Jun;26(6):973-5.
  113. Hayat SJ, Uppal SS. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol. 2007;17(2):174-7.
  114. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005 Jul;141(7):910-1
  115. Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol. 2006 Jan;142(1):17-9.
  116. Henes JC, Fritz J, Koch S, et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007; 26:1711-5.
  117. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004; 52:61-3.
  118. Hermann J, Reittner P, Scarpatetti M, Graninger W.Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis. 2006 May;65(5):691-2.
  119. Hobbs K. Chronic sarcoid arthritis treated with intraarticular etanercept. Artritis Rheum. 2005 Mar;52(3):987-8.
  120. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621-30.
  121. Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis. 2006 Mar;23(1):73-7.
  122. Huffstutter JE, Sienknecht CW.Treatment of resistant adult still disease with infliximab: a report of 2 cases. J Clin Rheumatol. 2004 Aug;10(4):218-21
  123. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46:1171-6.
  124. Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33:1802-4.
  125. Ideguchi H, Ohno S, Takase K, Hattori H, Kirino Y, Takeno M, Ishigatsubo Y. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology (Oxford). 2007 Oct;46(10):1621-2.
  126. Jacobson SH, van Vollenhoven R, Gunnarsson I. Rituximab-induced long-term remission of membranous lupus nephritis. Nephrol Dial Transplant. 2006 Jun;21(6):1742-3. Epub 2006 Jan 23.
  127. Jonsdottir T, Gunnarsson I, Risselada A, Welin Henriksson E, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2007.
  128. Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract. 2005;99(3):c92-6.
  129. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007 Jun;66(6):842-3.
  130. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006 Aug;65(8):1116-7.
  131. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-7.
  132. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003 Aug;30(8):1864-7
  133. Kleinert J, Lorenz M, Köstler W, Hörl W, Sunder-Plassmann G, Soleiman A. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr. 2004 May 31;116(9-10):334-8.
  134. Kobylecki C, Shaunak S. Refractory neurosarcoidosis responsive to infliximab. Pract Neurol. 2007 Apr;7(2):112-5.
  135. Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. Aprospective, non-comparative series of four patients. Clin Rheumatol. 2004 Feb;23(1):45-9.
  136. Korkmaz C, Temiz G, Cetinbas F, Buyukkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford) 2004; 43:937-8.
  137. Kotani T, Takeuchi T, Kawasaki Y, Hirano S, Tabushi Y, Kagitani M, Makino S, Hanafusa T. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus. 2006;15(10):683-5.
  138. Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Günaydin I, Kanz L. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007 Dec;37(3):189-97.
  139. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant. 2005 Jan;20(1):213-6.
  140. Koukoulaki M, Smith KG, Jayne DR.Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006 Apr;65(4):557-9.
  141. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001; 60 Suppl 3:iii55-7.
  142. Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46:118-21.
  143. Kuek A, Weerakoon A, Ahmed K, Ostör AJ.Adult-onset Still's disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept. Rheumatology (Oxford). 2007 Jun;46(6):1043-4.
  144. Kumar G, Kang CA, Giannini C. Neurosarcoidosis presenting as a cerebellar mass. J Gen Intern Med. 2007 Sep;22(9):1373-6. Epub 2007 Jul 6.
  145. Kumari R, Uppal SS. Prolonged remission in adult-onset Still's disease with etanercept. Clin Rheumatol. 2006 Feb;25(1):106-8.
  146. La Montagna G, Valentini G.Listeria monocytogenes meningitis in a patient receiving etanercept for Still's disease.Clin Exp Rheumatol. 2005 Jan-Feb;23(1):121.
  147. Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology (Oxford). 2004 Apr;43(4):531
  148. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood. 2007 Jan 15;109(2):845-6.
  149. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34:1636-7.
  150. Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 2005; 64:73-7.
  151. Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005 Jul;32(7):1369-70.
  152. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W, Gross WL. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003 Dec;62(12):1230-3.
  153. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-7.
  154. Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevi L. Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients. Presse Med 2005; 34:916-8.
  155. Le Roux K, Streichenberger N, Vial C, Petiot P, Feasson L, Bouhour F, Ninet J, Lachenal F, Broussolle C, Sève P Granulomatous myositis: a clinical study of thirteen cases. Muscle Nerve. 2007 Feb;35(2):171-7.
  156. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44:1542-5.
  157. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007; 22:24-7.
  158. Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P.[Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus] Ann Dermatol Venereol. 2006 Jan;133(1):53-5
  159. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminare experience in France. Ann Rheum Dis 2007.
  160. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601-7
  161. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G.Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis. 2003 Mar;62(3):280-1.
  162. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89:533-6.
  163. Mancini G, Erario L, Gianfreda R, Oliva A, Massetti AP, Mastroianni CM, Vullo V. Tuberculosis and Legionella pneumophila pneumonia in a patient receivinganti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment. Clin Microbiol Infect. 2007 Oct;13(10):1036-7.
  164. Mandel L, Wolinsky B, Chalom EC. Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case. J Am Dent Assoc. 2005 Sep;136(9):1282-5
  165. Marie I, Heliot P, Roussel F, Hervé F, Muir JF, Levesque H.nFatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford). 2005 Sep;44(9):1201-2.
  166. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270-6.
  167. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford). 2007 Jan;46(1):97-9
  168. Martinez Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2007.
  169. Massari M, Catania A, Magnani G. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Digestive and Liver Disease 39 Suppl. 1 (2007) S 134-135.
  170. Matsudaira R, Tamura N, Nawata M, Kaneda K, Takasaki Y. [Successful treatment with rituximab in a refractory Wegener's granulomatosis with hypertrophic pachymeningitis and the right orbital granuloma] Nippon Naika Gakkai Zasshi. 2007 Jul 10;96(7):1464-6
  171. Matzkies FG, Manger B, Schmitt-Haendle M, Nagel T, Kraetsch HG, Kalden JR, Schulze-Koops H. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis. 2003 Jan;62(1):81-2.
  172. Mayrbaeurl B, Hinterreiter M, Burgstaller S, Windpessl M, Thaler J. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007 Sep;26(9):1597-8.
  173. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32:98-105..
  174. Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol. 2005 Dec;11(6):314-8.
  175. Menon Y, Cucurull E, Espinoza LR. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford). 2003 Oct;42(10):1273-4
  176. Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004 Sep;328(3):173-5.
  177. Merino G, Varas G, Diaz G, et al. [Effectiveness of infliximab in patients with Behcet syndrome and severe uveoretinitis. Report of five cases]. Rev Med Chil 2006; 134:875-82.
  178. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol. 2003 Aug;2(4):413-4.
  179. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol. 2003 Jul;30(7):1624-5.
  180. Micheloud D, Nuño L, Rodríguez-Mahou M, Sánchez-Ramón S, Ortega MC, Aguarón A, Junco E, Carbone J, Fernández-Cruzl E, Carreño L, López-Longo FJ.Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus. 2006;15(12):881-5
  181. Milman N, Sørensen TB. [Treatment of severe sarcoidosis using TNF-alpha-inhibitor (infliximab)] Ugeskr Laeger. 2006 Jan 30;168(5):484-5.
  182. Minami R, Miyamura T, Watanabe H, Takahama S, Yamamoto M, Suematsu E. [Successful treatment of a patient with refractory Wegener's granulomatosis by rituximab] Nihon Rinsho Meneki Gakkai Kaishi. 2007 Apr;30(2):133-8
  183. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007 Sep;34(9):1864-8.
  184. Monti G, Saccardo F. Emergency in cryoglobulinemic síndrome: what to do?. Digestive and Liver Disease 39 Suppl. 1 (2007) S 112-115.
  185. Moosig F, Zeuner R, Renk C, Schröder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus. 2004;13(8):605-6.
  186. Mpofu S, Estrach C, Curtis J, Moots RJ. Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab. Rheumatology (Oxford). 2003 Sep;42(9):1117-8.
  187. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001; 358:1644.
  188. Murakami K, Fujii T, Yukawa N, Yoshifuji H, Kawabata D, Tanaka M, Usui T, Mimori T. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Mod Rheumatol. 2007;17(2):167-70.
  189. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 2007; 21:824-5.
  190. Mylona E, Golfinopoulou S, Samarkos M, Fanourgiakis P, Papadakos V, Skoutelis A. Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol. 2007 Dec 20.
  191. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford). 2005 Mar;44(3):410-1. Epub 2005 Jan 18.
  192. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66:1259-62.
  193. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46:1161-4.
  194. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses.  J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S139-42.
  195. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33:1021-6.
  196. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31:1362-8.
  197. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, Katoh N, Kishimoto S, Shimazaki C. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006 Jan;20(1):172-3.
  198. Olivieri I, de Stefano G, Padula A, La Gala A, de Stefano C. Infliximab in a case of early adult-onset Still's disease. Clin Rheumatol. 2003 Oct;22(4-5):369-70.
  199. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005 May-Jun;34(3):229-32.
  200. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005 Apr;64(4):630-3
  201. Pekow J, Chung RT. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol. 2006 May-Jun;40(5):450. No abstract available.
  202. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 2002 Feb;116(2):465-7.
  203. Petrarca A, Rigacci L, Monti M, Giannini C, Benardi F, Caini P, Colagrande S, Bosi A, Laffi G, Zignego. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. . Digestive and Liver Disease 39 Suppl. 1 (2007) S 129-133.
  204. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002 Nov 26;59(10):1660-1.
  205. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab.J Am Acad Dermatol. 2005 Nov;53(5):917.
  206. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740-50.
  207. Prescott K, Costner M, Cohen S, Kazi S.Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am J Med Sci. 2007 Mar;333(3):137-9.
  208. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63:318-20.
  209. Quartuccio L, De Vita S. Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still's disease. J Rheumatol. 2007 Apr;34(4):892-3.
  210. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45:842-6.
  211. Raflores MB, Kaplan RB, Spero JA. Pre-operative management of a patient with hypoprothrombinemia-lupus anticoagulant syndrome. Thromb Haemost. 2007 Jul;98(1):248-50.
  212. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1733-5.
  213. Richez C, Dumoulin C, Coutouly X, Schaeverbeke T. Successful treatment of relapsing polychondritis with infliximab. Clin Exp Rheumatol. 2004 Sep-Oct;22(5):629-31.
  214. Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab. Clin Rheumatol. 2006 Nov;25(6):891-4.
  215. Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford). 2006 Jul;45(7):915-6. Epub 2006 May 11.
  216. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003 Nov;124(5):2028-31.
  217. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology(Oxford). 2001 Apr;40(4):473-4.
  218. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19:3054-61.
  219. Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 2002; 41:1194-5.
  220. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. 2002 Mar;61(3):283-4.
  221. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006 Feb;33(2):355-7.
  222. Rudinskaya A, Trock DH.Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol. 2003 Oct;9(5):330-2
  223. Ruiz PJ, Masliah E, Doherty TA, Quach A, Firestein GS. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis. 2007 Mar;66(3):422-3.
  224. Saadoun D, Deslandre CJ, Allanore Y, Pham XV, Kahan A. Sustained response to infliximab in 2 patients with refractory relapsing polychondritis.J Rheumatol. 2003 Jun;30(6):1394-5.
  225. Sabugo F, Llanos C, Soto L, Gutierrez J, Cuchacovich M. [Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case]. Rev Med Chil 2005; 133:681-4.
  226. Saigal K, Valencia IC, Cohen J, Kerdel FA. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol 2003; 49:S283-5.
  227. Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003; 12:798-800.
  228. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol. 2006 Dec;41(6):766-8.
  229. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100:2053-9.
  230. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007; 146:631-9.
  231. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50:2240-5.
  232. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101:3818-26.
  233. Sarwar H, McGrath H, Jr., Espinoza LR. Successful treatment of long-standing neuro-Behcet's disease with infliximab. J Rheumatol 2005; 32:181-3.
  234. Sayarlioglu M, Cinal A, Topcu N, Demirok A. Effect of infliximab on refractory uveitis in Behcet's disease. Ann Pharmacother 2004; 38:901-2.
  235. Scheinberg M, Hamerschlak N, Kutner JM, Ribeiro AA, Ferreira E, Goldenberg J, Kiss MH, Chahade WH. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).Clin Exp Rheumatol. 2006 Jan-Feb;24(1):65-9.
  236. Scheinberg MA.Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol. 2002 Sep-Oct;20(5):733-4
  237. Selva-O'Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004; 43:1196-7.
  238. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007; 66:351-7.
  239. Sève P, Gachon E, Petiot P, Stankovic K, Charhon A, Broussolle C. Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren's syndrome. Rheumatol Int. 2007 Dec;28(2):175-177
  240. Seyahi E, Hamuryudan V, Hatemi G, Melikoglu M, Celik S, Fresko I, Yurdakul S, Yazici H. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome. Rheumatology (Oxford). 2007 Jul;46(7):1213-4
  241. Seymour MW, Home DM, Williams RO, Allard SA. Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis. Rheumatology (Oxford). 2007 Nov;46(11):1738-9.
  242. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17:550-7.
  243. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004; 140:404-6.
  244. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358:295-6.
  245. Shih WJ, Ghesani N, Hongming Z, Alavi A, Schusper S, Mozley D. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med. 2002 Feb;27(2):142-3
  246. Simon Z, Tarr T, Ress Z, Gergely L, Kiss E, Illes A.Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma Rheumatol Int. 2007 Dec;28(2):179-83.
  247. Slovis BS, Eyler AE. A 33-year-old man with pharyngitis, transient rash, and multiorgan system failure. Chest. 2007 Sep;132(3):1080-3
  248. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006 Sep;54(9):2970-82.
  249. Sollberger M, Fluri F, Baumann T, Sonnet S, Tamm M, Steck AJ, Brutsche M. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol. 2004 Jun;251(6):760-1.
  250. Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ; American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum. 2003 Jun 15;49(3):394-8.
  251. Sommer A, Altmeyer P, Kreuter A. A case of mucocutaneous Behcet's disease responding to etanercept. J Am Acad Dermatol 2005; 52:717-9.       
  252. Sorrentino D, Avellini C, Zearo E. Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale. Inflamm Bowel Dis. 2004 Jul;10(4):438-40.
  253. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001 Dec;44(12):2836-40.
  254. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford). 2004 Apr;43(4):524-6.
  255. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.Rheumatology (Oxford). 2006 Nov;45(11):1432-6
  256. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001; 44:2371-5.
  257. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129.
  258. Svozílková P, Ríhová E, Brichová M, Diblík P, Kuthan P, Poch T.[Infliximab in the treatment of Wegener's granulomatosis: case report]Cesk Slov Oftalmol. 2006 Jul;62(4):280-6.
  259. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005; 53:788-91.
  260. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford). 2005 Apr;44(4):561-2.
  261. Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol. 2008;18(1):72-5.
  262. Takamoto M, Kaburaki T, Numaga J, Fujino Y, Kawashima H. Long-term infliximab treatment for Behcet's disease. Jpn J Ophthalmol 2007; 51:239-40
  263. Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med. 2007;46(7):409-14
  264. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D.Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003 Apr;62(4):373-4.
  265. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17:191-7.
  266. Tektonidou MG, Skopouli FN. Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis. Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S103.
  267. Thonhofer R, Soleiman A, Kriessmayr M, Thonhofer U, Wipfler E, Gaugg M, Eder S, Erlacher L. Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy. Scand J Rheumatol. 2006 Nov-Dec;35(6):485-8.
  268. Tiliakos A 4th, Shaia S, Hostoffer R, Kent L. The use of infliximab in a patient with steroid-dependent churg-strauss syndrome. J Clin Rheumatol. 2004 Apr;10(2):96-7.
  269. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005; 44:176-82.
  270. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66:470-5.
  271. Torrente SV, Guerri RC, Perez-Garcia C, Benito P, Carbonell J. Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-alpha. Intern Med J 2007; 37:280-1.
  272. Toth C, Martin L, Morrish W, Coutts S, Parney I. Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurol Scand. 2007 Oct;116(4):259-62.
  273. Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2007.
  274. Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol. 2006 Jul-Aug;35(4):323-5.
  275. Trappe R, Loew A, Thuss-Patience P, Dörken B, Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab--monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol. 2006 Feb;85(2):134-5.
  276. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factoralpha antibody. Gut. 2001 Nov;49(5):725-8.
  277. Triolo G, Vadalà M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, Citarrella P, Lodato G, Licata G. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis. 2002 Jun;61(6):560-1
  278. Tuchinda C, Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol. 2006 Jun;5(6):538-40
  279. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005; 52:2478-84.
  280. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003 Dec;48(12):3542-3
  281. Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol. 2007 Jul;143(7):873-7.
  282. Uthman I, El-Sayad J.b Refractory polymyositis responding to infliximab. Rheumatology (Oxford). 2004 Sep;43(9):1198-9.
  283. Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2006; 25:109-10.
  284. Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol. 2007 Nov;26(11):2001-3. Epub 2007 Mar 30.
  285. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-85
  286. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8:R167.
  287. Van den Bergh B, Selleslag D, Boelaert JR, et al. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature. Acta Clin Belg 2005; 60:102-5.
  288. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007; 66:565-6.
  289. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33:423-7.
  290. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra.Ann Rheum Dis. 2005 Apr;64(4):647-8
  291. Veneri D, Ambrosetti A, Franchini M, Mosna F, Poli G, Pizzolo G.Remission of severe antiphospholipid syndrome associated with non-Hodgkin's B-cell lymphoma after combined treatment with rituximab and chemotherapy.Haematologica. 2005 Nov;90 Suppl:ECR37
  292. Visentini M, Granata M, Veneziano ML, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007; 125:30-3.
  293. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006; 65:1033-7.
  294. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford). 2006 Apr;45(4):491-2.
  295. Waite L, Morrison E. Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy).Lupus. 2007;16(10):841-2.
  296. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 2004; 22:S14-6.
  297. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003; 12:779-82.
  298. Wendling D, Prati C, Ornetti P, Toussirot E, Streit G. [Anti TNF-alpha treatment of a refractory polymyositis] Rev Med Interne. 2007 Mar;28(3):194-5.
  299. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002 Nov 1;100(9):3426-8
  300. Yamamoto M, Takahashi H, Miyamoto C, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, Shinomura Y, Nonaka M, Imai K. [A case in which the subject was affected by Listeia meningoencephalitis during administration of infliximab for steroid-dependent adult onset Still's disease].Nihon Rinsho Meneki Gakkai Kaishi. 2006 Jun;29(3):160-8.
  301. Yamout B, El-Hajj T, Barada W, Uthman I. Successful treatment of refractory neuroSjogren with Rituximab. Lupus. 2007;16(7):521-3.
  302. Yee AM, Pochapin MB.Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001 Jul 3;135(1):27-31.
  303. Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behcet's disease. Rheumatology (Oxford) 2004; 43:394-6.
  304. Zaenker M, Arbach O, Helmchen U, Glorius P, Ludewig S, Braasch E. Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: first report on the efficacy of primary anti-TNF-alpha treatment. Int J Tissue React. 2004;26(3-4):85-92.
  305. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-34.
  306. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004; 31:96-101.
  307. Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjögren keratoconjunctivitis sicca treated with rituximab. Cornea. 2007 Aug;26(7):886-7.